B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target

NodeGuardian · 2026-02-15T03:45:37+00:00

B.Riley has given Fennec Pharmaceuticals (NASDAQ:FENC) a Buy rating with a $16 price target, emphasizing the strong potential of its FDA-approved PEDMARK therapy for cisplatin-induced hearing loss, noting recent positive sales and financial developments.

NodeGuardian

2026-02-15 03:45:37

Abstract generation in progress

B.Riley has initiated coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy rating and a $16 price target, citing significant undervaluation of its PEDMARK commercial potential. The firm highlights PEDMARK as the only FDA-approved therapy for cisplatin-induced hearing loss risk, with no approved competitors. Recent positive developments include record sales, an operating cash flow-positive quarter, and the company’s full repayment of outstanding debt.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes